Package Leaflet: Information for the User
Descovy 200 mg/25 mg film-coated tablets
emtricitabine/tenofovir alafenamide
This medicine is subject to additional monitoring, which will help to quickly identify new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack and other information
Descovy contains two active substances:
Descovy blocks the action of an enzyme called reverse transcriptase, which is essential for the multiplication of the virus. Therefore, Descovy reduces the amount of HIV present in the body.
Descovy, in combination with other medicines, is used to treat HIV-1 infectionin adults and adolescents aged 12 years and older, who weigh at least 35 kg.
Do not take Descovy:
Warnings and precautions
You must remain under the supervision of your doctor while taking Descovy.
While taking this medicine, you can still transmit HIV to others, even if effective antiretroviral therapy reduces the risk. Ask your doctor about the precautions needed to avoid infecting others. This medicine is not a cure for HIV infection. While you are taking Descovy, you may still develop infections or other illnesses associated with HIV.
Consult your doctor before taking Descovy:
If you have hepatitis B, liver problems may worsen after stopping Descovy. Do not stop taking Descovy without talking to your doctor first: see section 3, Do not stop taking Descovy.
While taking Descovy
Once you start taking Descovy, be aware of:
Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems if you take Descovy for a long time.
Children and adolescents
Do not give this medicine to childrenaged 11 years or younger or weighing less than 35 kg.
Descovy has not been studied in children aged 11 years or younger.
Other medicines and Descovy
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.Descovy may interact with other medicines. As a result, the levels of Descovy or other medicines in your blood may change. This may prevent your medicines from working properly or may increase the risk of side effects. In some cases, your doctor may need to adjust the dose or check your blood levels.
Medicines used to treat hepatitis B virus infection:
Do not take Descovy with medicines that contain:
Other types of medicines:
Consult your doctor if you are taking:
76
Pregnancy and breastfeeding
Consult your doctor or pharmacist before taking any medicine if you are pregnant.
If you have taken Descovy during your pregnancy, your doctor may ask for regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV was greater than the risk of side effects.
Do not breastfeed your child while taking Descovy.This is because one of the active substances of this medicine passes into breast milk. It is recommended that you do not breastfeed to avoid transmitting the virus to your child through breast milk.
Driving and using machines
Descovy may cause dizziness. If you feel dizzy while taking Descovy, do not drive or use tools or machines.
Always take this medicine exactly as your doctor has told you.
If you are not sure, consult your doctor or pharmacist again.
The recommended dose is:
Adults:one tablet a day, with or without food
Adolescents aged 12 years or older, weighing at least 35 kg:one tablet a day, with or without food
Do not chew, crush, or split the tablet.
Always take the dose recommended by your doctor.This is to ensure that your medicine is completely effective and to reduce the risk of developing resistance to treatment. Do not change the dose unless your doctor tells you to.
If you are on dialysis,take the daily dose of Descovy after dialysis is finished.
If you take more Descovy than you should
If you take more than the recommended dose of Descovy, you may be at greater risk of side effects from this medicine (see section 4, Possible side effects).
Consult your doctor immediately or go to the emergency room. Bring the pack of tablets with you to show what you have taken.
If you forget to take Descovy
It is important that you do not miss a dose of Descovy.
If you forget a dose:
If you vomit within 1 hour after taking Descovy,take another tablet.
Do not stop taking Descovy
Do not stop taking Descovy without talking to your doctor first.Stopping Descovy may seriously affect the success of future treatments. If Descovy is stopped for any reason, consult your doctor before restarting Descovy.
When you notice that you have little Descovy left,go to your doctor or pharmacist to get more. This is very important because the amount of virus can start to increase if the medicine is stopped, even for a short time. Your illness may then become more difficult to treat.
If you have both HIV and hepatitis B infection,it is very important not to stop taking Descovy without first talking to your doctor. You may need to have blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment can cause the hepatitis to worsen, which can be life-threatening.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects: tell a doctor immediately
Very common side effects
(may affect more than 1 in 10 people)
Common side effects
(may affect up to 1 in 10 people)
Uncommon side effects
(may affect up to 1 in 100 people)
Other effects that may be seen during HIV treatment
The frequency of the following side effects cannot be estimated from the available data.
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly due to the recovery of health and lifestyle, and in the case of blood lipids, sometimes due to the HIV medicines themselves. Your doctor will monitor these changes.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month.
Store in the original package to protect from moisture. Keep the bottle tightly closed.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Descovy composition
The active ingredients areemtricitabine and tenofovir alafenamide. Each Descovy film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.
The other ingredients are
Tablet core:
Microcrystalline cellulose, sodium croscarmellose, magnesium stearate.
Film coating:
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, aluminum lake indigo carmine (E132).
Appearance and packaging of the product
Descovy film-coated tablets are blue, rectangular tablets, marked on one side with “GSI” and on the other with the number “225”.
Descovy is available in bottles of 30 film-coated tablets (with a silica gel desiccant that should be kept in the bottle to help protect the tablets). The silica gel desiccant is contained in a separate sachet or container and should not be swallowed.
This medication is available in packs of 1 bottle of 30 film-coated tablets and in packs of 60 (2 bottles of 30) and 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.
Marketing authorization holder:
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer:
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
For further information about this medication, please contact the local representative of the marketing authorization holder:
Belgium Gilead Sciences Belgium SPRL-BVBA Gilead Sciences Belgium SPRL- | Lithuania Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 |
Bulgaria Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Luxembourg Gilead Sciences Belgium SPRL-BVBA Gilead Sciences Belgium SPRL- |
Czech Republic Gilead Sciences s.r.o. Tel: + 420 910 871 986 | Hungary Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Denmark Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Germany Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Netherlands Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Estonia Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 | Norway Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Greece Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Austria Gilead Sciences GesmbH Tel: + 43 1 260 830 |
Spain Gilead Sciences, S.L. Tel: + 34 91 378 98 30 | Poland Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 |
France Gilead Sciences Gilead Sciences 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 21 7928790 |
Croatia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Romania Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: +353 (0) 214 825 999 Iceland Gilead Sciences Sweden AB Gilead Sciences Sweden AB | Slovenia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 Slovakia Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210 |
Italy Gilead Sciences S.r.l. Tel: + 39 02 439201 | Finland Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Cyprus Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Sweden Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvia Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 | United Kingdom Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700 |
Date of last revision of this leaflet:<{MM/AAAA}> <{month AAAA}>.
Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.